Table 1.
Patient characteristics
Demographics of 102,549 HSCT (allogeneic 37,542; 37% and autologous 65,007; 63%) between 1999 and 2006 in Europe.
| Allogeneic HSCT | Autologous HSCT | Total | |
|---|---|---|---|
| N centers | 299 | 401 | 404 |
| JACIE⁎ accredited | 119 | 133 | 135 |
| JACIE⁎ not accredited | 180 | 268 | 269 |
| N Patients | 37,542 | 65,007 | 102,549 |
| Male % | 21,797 (58.2%) | 38,089 (58.7%) | 59,886 (58.5%) |
| Age | |||
| Median (years) | 39·2 | 53·4 | 49·1 |
| < 20 years | 7326 (20%) | 2240 (3%) | 9566 (9%) |
| 20–40 years | 12,055 (32%) | 11,800 (18%) | 23,855 (23%) |
| 40–60 years | 15,563 (41%) | 33,973 (52%) | 49,536 (48%) |
| > 60 years | 2598 (7%) | 16,994 (26%) | 19,592 (19%) |
| Disease | |||
| Acute leukemia | 21,991 (59%) | 6361 (10%) | 28,352 (27%) |
| Chronic leukemia | 7486 (20%) | 1556 (2%) | 9042 (9%) |
| MDS/MPS | 3864 (10%) | 232 (< 1%) | 4096 (4%) |
| Lymphoma | 3307 (9%) | 32,358 (50%) | 35,665(35%) |
| PCD | 894 (2%) | 24,500 (38%) | 25,394 (25%) |
| Year Transplant | |||
| 1999–2002 | 17,589 (47%) | 29,368 (45%) | 46,957 (46%) |
| 2003–2006 | 19,953 (53%) | 35,639 (55%) | 55,592 (54%) |
| 0–I | 5444(15%) | 3755 (6%) | 9199 (9%) |
| II–III | 16,680 (44%) | 35,623 (55%) | 52,303 (51%) |
| IV–V | 13,352 (36%) | 25,629 (39%) | 38,981 (38%) |
| VI–VII | 2066 (5%) | 0 | 2066(2%) |
⁎
JACIE = Joint Accreditation Committee of the International Society for Cellular Therapy and the European Society for Blood and Marrow Transplantation (www.jacie.org).